Results
|
1.
|
Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines. MedStar authors:
- Asch, Federico M
- Barac, Ana
- Herbolsheimer, Pia M
- Lynce, Filipa
- Mete, Mihriye
- Nunes, Raquel
- Shara, Nawar M
- Swain, Sandra M
- Wray, Lynette
Year: 2016
Citation: - Breast Cancer Research & Treatment. 155(2):285-93, 2016 Jan.
Institution:
- MedStar Health Research Institute
- MedStar Health Research Institute
- MedStar Health Research Institute
- MedStar Washington Hospital Center
- MedStar Washington Hospital Center
- Washington Cancer Institute
- Washington Cancer Institute
- Washington Cancer Institute A
- Washington Cancer Instituteia
Department:
- MedStar Heart Institute
- MedStar Heart Institute
Medline publication type:
All authors: - Asch FM, Barac A, Herbolsheimer P, Isaacs C, Lynce F, Mete M, Nardacci MP, Nunes RA, Peshkin BN, Shara NM, Smith KL, Swain SM, Warren R, Wray L
|
|
2.
|
BRCA1/2 mutations and risk-reducing bilateral salpingo-oophorectomy among Latinas: The UPTAKE study. MedStar authors:
- Lynce, Filipa
- Schlam, Ilana
Year: 2021
Citation: - Journal of Genetic Counseling. 30(2):383-393, 2021 04.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Ahn J, Campos C, Denduluri N, Dutil J, Friedman S, Geng X, Graves KD, Isaacs C, Lynce F, Nahleh Z, Peshkin BN, Ricker C, Rodriguez P, Schlam I
|
|
3.
|
Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer. MedStar authors:
Year: 2021
Citation: - JCO Precision Oncology. 5, 2021.
Institution: - MedStar Union Memorial Hospital
Department: - Internal Medicine Residency
Medline publication type:
All authors: - Adra N, Agarwal N, Aggarwal R, Albany C, Alva AS, Antonarakis ES, Ashkar R, Barata P, Bastos D, Berchuck JE, Bryce A, Cheng HH, Fu W, Holler AE, Kessel A, Marshall CH, Nafissi N, Sartor AO, Smaletz O, Sokolova AO, Sternberg CN, Su C, Taplin ME, Taza F, Vlachostergios PJ, Wang H
|
|
4.
|
Retrospective Cohort Study on the Limitations of Direct-to-Consumer Genetic Screening in Hereditary Breast and Ovarian Cancer. MedStar authors:
Year: 2023
Citation: - JCO Precision Oncology. 7:e2200695, 2023 08.
Department:
- Hematology & Oncology Fellowship
- MedStar Georgetown University Hospital/MedStar Washington Hospital Center
Medline publication type:
All authors: - Anderson MJ, Barrows ED, Desai NV, Esplin ED, Hatchell KE, Haverfield EV, Herrera B, Isaacs C, Lucassen A, Nielsen SM, Tung NM
|
|
5.
|
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer. MedStar authors:
Year: 2024
Citation: - Journal of Clinical Oncology. 42(11):1288-1300, 2024 Apr 10.
Institution: - MedStar Franklin Square Medical Center
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
All authors: - Ganz PA, Bandos H, Spanic T, Friedman S, Muller V, Kuemmel S, Delaloge S, Brain E, Toi M, Yamauchi H, de Duenas EM, Armstrong A, Im SA, Song CG, Zheng H, Sarosiek T, Sharma P, Geng C, Fu P, Rhiem K, Frauchiger-Heuer H, Wimberger P, t'Kint de Roodenbeke D, Liao N, Goodwin A, Chakiba-Brugere C, Friedlander M, Lee KS, Giacchetti S, Takano T, Henao-Carrasco F, Virani S, Valdes-Albini F, Domchek SM, Bane C, McCarron EC, Mita M, Rossi G, Rastogi P, Fielding A, Gelber RD, Scheepers ED, Cameron D, Garber J, Geyer CE, Tutt ANJ
|
|
6.
|
|